Aortic valve stenosis is the most prevalent valvular heart disease in developed countries, with its incidence rising in ageing populations. Transcatheter aortic valve implantation has transformed management, extending eligibility from high-surgical-risk patients to those with low risk. Long-term durability data and optimal antithrombotic strategies post-TAVI remain active areas of clinical inquiry.
PRO-TAVI: Deferring PCI Before TAVI Non-Inferior to Routine PCI
The PRO-TAVI trial demonstrated that deferring percutaneous coronary intervention (PCI) before transcatheter aortic valve implantation (TAVI) is non-inferior to routine PCI.
Emboliner Non-Inferior to Sentinel for TAVR Cerebral Protection
ACC.26 trial shows Emboliner embolic protection catheter is non-inferior to Sentinel system during TAVR for preventing cerebral lesions.
TAVI and Aortic Dissection Risk: Is Valve Type a Factor?
Delayed aortic dissection following TAVI remains a rare, but devastating, complication. The question is whether balloon-expandable valves present a unique biomechanical risk compared to self-expanding alternatives.
Your TCAR TAVR patients face stroke. SSEPs could make the difference.
Patients undergoing transcarotid transcatheter aortic valve replacement (TCAR TAVR) face stroke risk. Monitoring SSEPs could flag cerebral hypoperfusion early, prompting swift intervention.